Selected References


 

Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, and Mattick RP. 

(2005) An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4):321-9. doi:10.1016/j.jsat.2005.02.007.

Bell J, Trinh L, Butler B, Randall D, and Rubin G.

(2009) Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104(7):1193-200. doi:10.1111/j.1360-0443.2009.02627.x. 

Berg ML, Idrees U, Ding R, Nesbit SA, Liang HK, and McCarthy ML.

(2007) Evaluation of the use of buprenorphine for opioid withdrawal in an emergency department. Drug Alcohol Depend. 2007;86(2-3):239-44. doi:10.1016/j.drugalcdep.2006.06.014. 

Bhatraju E, Grossman E, Tofighi B, McNeely J, DiRocco D, Flannery M, Garment A, Goldfeld K, Gourevitch M and Lee J.

(2017) Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addict Sci Clin Pract. 2017; 12:7 DOI 10.1186/s13722-017-0072-2

Cunningham C, Roose R, Starrels J, Giovanniello A, Sohler N.

(2013) Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. J Addict Med. 2013 Jul-Aug; 7(4): 287–293. doi:  10.1097/ADM.0b013e31829727b2

Clark RE, Samnaliev M, Baxter JD, and Leung GY. 

(2011) The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011;30(8):1425-33. doi:10.1377/hlthaff.2010.0532

Cunningham CO, Roose RJ, Starrels JL, Giovanniello A, Sohler NL.

(2013) Prior Buprenorphine Experience Is Associated With Office-Based Buprenorphine Treatment Outcomes. J Addict Med 2013 Jul-Aug;7(4):287-93. doi: 10.1097/ADM.0b013e31829727b2.

D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, and Fiellin DA. 

(2015) Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-44. doi:10.1001/jama.2015.3474

D’Onofrio, G, Chawarski M, O'Connor P, Pantalon M, Busch S, Owens P, Hawk K, Bernstein S, Fiellin D.

(2017) Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. J Gen Intern Med. 2017; 32(6):660–6 doi:10.1007/s11606-017-3993-2

Fugelstad A, Stenbacka M, Leifman A, Nylander M, and Thiblin I. 

(2007) Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction. 2007;102(3):406-12. doi:10.1111/j.1360-0443.2006.01714.x.

Gowing L, Farrell M, Bornemann R, and Ali R.

(2008) Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004145. doi: 10.1002/14651858.CD004145.pub3. 

Larochelle MR, Bernson D, Land T, Stopka T, Wang N, Xuan Z, Bagley S, Liebschutz J, Walley A.

(2018) Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.  Ann Intern Med. [Epub ahead of print 19 June 2018] doi: 10.7326/M17-3107

Lee J, Grossman E, DiRocco D, Gourevitch M.

(2009) Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009 Feb;24(2):226-32. doi: 10.1007/s11606-008-0866-8. 

Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, and Robertson JR. 

(2010) Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ. 2010;341(jul01 1):c3172-c3172. doi:10.1136/bmj.c3172.

Marsden, J, Stillwell, G, Jones, H, Cooper, A, Eastwood, B, Farrell, M, Lowden, T, Maddalena, N, Metcalfe, C, Shaw, J, and Hickman, M.

(2017) Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction, 112: 1408–1418. doi: 10.1111/add.13779.

Mattick RP, Breen C, Kimber J, and Davoli M.

(2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207. doi:10.1002/14651858.CD002207.pub4. 

Pierce M, Bird SM, Hickman M, Marsden J, Dunn G, Jones A, and Millar T.

(2016) Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016;111(2):298-308. doi:10.1111/add.13193. 

Raffa, R.B., Haidery, M., Huang, H.M., Kalladeen, K., Lockstein, D.E., Ono, H., Shops, M.J., Sowunmi, O.A., Tran, J.K.

(2014) The clinical analgesic efficacy of buprenorphine. Journal of Clinical Pharmacy and Therapeutics. 2014; 39, 577-583. doi.org/10.1111/jcpt.12196.

Sordo L, Barrio G, Bravo M, Indave B, Degenhardt L, Wiessig L, Ferri M, Pastor-Barriuso R.

(2017) Mortality Risks During and After Opioid Substitution Treatment: Systematic Review and Meta-Analysis of Cohort Studies. BMJ 2017; 357:j1550.

Sigmon S, Ochalek T, Meyer A, Hruska B, Heil S, Badger G, Rose, G, Brooklyn J.

(2016) Interim Buprenorphine vs. Waiting List for Opioid Dependence. N Engl J Med.375;25 nejm.org December 22, 2016.

Sporer KA. 

(2003) Strategies for preventing heroin overdose. BMJ. 2003;326(7386):442-4. doi:10.1136/bmj.326.7386.442

Ward J, Hall W, and Mattick RP.

(1999) Role of maintenance treatment in opioid dependence. Lancet. 1999;353(9148):221-6. doi:10.1016/S0140-6736(98)05356-2.